Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to assess the impact of CRMD-001 on markers of
contrast-induced acute kidney injury (AKI) in high-risk patients with chronic kidney disease
(CKD) undergoing coronary angiography and PCI.